Today: 21 May 2026
‘No reasons to own’? AI agent fears slam software stocks after Anthropic’s Claude Cowork debut

‘No reasons to own’? AI agent fears slam software stocks after Anthropic’s Claude Cowork debut

NEW YORK, Jan 20, 2026, 10:38 EST

  • A basket of software-as-a-service stocks tracked by Morgan Stanley has dropped roughly 15% so far this year, following an 11% decline in 2025.
  • Intuit dropped 16% last week, with Adobe and Salesforce tumbling over 11%, as a fresh AI tool from Anthropic sparked fresh disruption fears.
  • Anthropic’s Claude Cowork has intensified investor concerns over the potential for “AI agents” to disrupt subscription software models. Semafor

U.S. software stocks are off to their worst start in years, as investors question if a fresh wave of AI tools could replace pricey, seat-based subscriptions from long-standing vendors.

The selloff is sharpening a well-worn divide in tech. The Nasdaq 100 stays close to record highs, while certain software stocks have slid to multi-year lows. Meanwhile, a Morgan Stanley basket tracking SaaS — subscription software delivered online — just hit its lowest valuation ever.

The threat landscape is shifting. Anthropic’s latest launches—like its “Cowork” tool and a healthcare-specific product—have unsettled investors who believed enterprise software was safe thanks to regulation, data, and workflow barriers, Business Insider reported.

Cowork is described as an “agent” — software designed to plan and execute tasks, not merely respond to queries. Anthropic claims the tool can compile spreadsheets from screenshots, draft reports using scattered notes, and sometimes operate across files and apps. Still, the company cautions about potential security risks and errors from relying on an automated assistant. TechRadar

Skeptics argue the market is betting on a disaster before the facts are clear. William Blair analyst Arjun Bhatia described Cowork as “the latest Boogeyman in software,” telling Barron’s the selloff “seems overdone.” Barron’s

The contrarian argument hinges on what incumbents still hold: distribution channels, customer ties, and exclusive data. MarketWatch highlighted investors noting Salesforce’s Agentforce rollout and Snowflake’s AI-driven revenue gains as evidence some big players are carving out ways to profit from AI instead of being sidelined by it.

Some argue the sell-off makes sense. Salesforce dropped 6.5% in a single day last week, while Adobe tumbled 5.4% to hit a multi-year low. Investors are skeptical about whether AI-fueled productivity gains will actually reduce the need for existing tools, and if the early AI features will deliver lasting revenue, reported.

The developer tooling surge is fueling the story. A Sherwood News columnist argued last week that “Claude Code is the ChatGPT moment repeated,” warning it might spell “awful news for software stocks.” Sherwood News

That buzz is tangible on the ground. Over 150 attendees crammed into a Claude Code meetup in Seattle, where a product engineer highlighted “closing the feedback loop” as the game changer — letting the tool act, evaluate outcomes, and then iterate. GeekWire

Investors, however, are bracing for a bumpier ride. AI agents may improve, but firms must still entrust them with sensitive data and key operations. The “per-seat” licensing model might turn out more stubborn than expected if companies restrict automation over compliance, security, or accountability concerns. Investors

The risk is straightforward: if agents get good enough to take over specific software tasks, subscription pricing could weaken, turning today’s “cheap” multiples into a value trap. Doug O’Laughlin of Fabricated Knowledge labeled this shift an “extinction-level event” for certain horizontal software segments, suggesting the industry might have to rethink both its products and its target customers. fabricatedknowledge.com

Stock Market Today

  • Installed Building Products Stock: Revenue and Earnings Growth Slow Amid Market Underperformance
    May 20, 2026, 10:53 PM EDT. Installed Building Products' stock fell 15.9% to $208.38 over six months, underperforming the S&P 500's 13.3% gain. The slowdown in revenue growth to 2.4% annualized over two years contrasts with a 5-year trend of 11.7%. Earnings per share growth also lagged at 2.6%, reflecting persistent but subdued profitability. The stock trades at a forward price-to-earnings ratio of 20.8, indicating a fair valuation but limited near-term optimism. Analysts highlight a cautious outlook due to softer quarterly results and unproven impact from new offerings, suggesting investors may find better opportunities elsewhere.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Bitcoin price slides toward $90,000 as Trump’s Greenland tariff threat hits risk appetite
Previous Story

Bitcoin price slides toward $90,000 as Trump’s Greenland tariff threat hits risk appetite

Amazon’s AWS European Sovereign Cloud Is Powering New “Forever Portfolio” Stock Picks — Here’s Who Else Made the Cut
Next Story

Amazon’s AWS European Sovereign Cloud Is Powering New “Forever Portfolio” Stock Picks — Here’s Who Else Made the Cut

Go toTop